曲安奈德
糖尿病性视网膜病变
纳米载体
药物输送
体内
药理学
医学
糖基化
视网膜
眼球后段
眼科
血管内皮生长因子
药品
化学
糖尿病
癌症研究
内分泌学
材料科学
血管内皮生长因子受体
纳米技术
生物
神经科学
生物技术
作者
M Sharadha,N. Vishal Gupta,Mohamed Rahamathulla,Mohammed Muqtader Ahmed,Syeda Ayesha Farhana,Riyaz Ali M. Osmani,Balamuralidhara Veeranna,KB Koteshwara
标识
DOI:10.1016/j.ijpharm.2023.123443
摘要
The expression of inflammatory markers and vascular endothelial growth factor (VEGF) was found to be upregulated in various posterior ocular disorders, including diabetic retinopathy (DR). Effective delivery of therapeutic agents to the retina poses a significant challenge in ophthalmic drug delivery due to biological ocular barriers. Triamcinolone acetonide (TA) was selected as the model corticosteroid drug targeting cytokines and VEGF in DR. However, despite TA’s low molecular weight and hydrophobicity, which enable it to bypass the conjunctival epithelial barrier, it doesn’t efficiently exert its effect at the target site. Nanocarriers have emerged as a solution to enhance drug delivery to the retina and improve bioavailability. This study aimed to compare the effects of Triamcinolone-loaded cubic liquid crystalline nanoparticles (TA-cubic LCNPs) and TA-Suspension in an experimental DR model administered via the subconjunctival (SCJ) route. The results demonstrated that TA-cubic LCNPs enhanced TA periocular delivery efficacy by reducing inflammatory and VEGF markers through the advanced glycation end products (AGE)/protein kinase C pathway. They were identified as promising nano-carriers, exhibiting potential for targeted delivery to the retina.
科研通智能强力驱动
Strongly Powered by AbleSci AI